Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
FDA OKs Nippon Shinyaku’s PII Plan for Exon 44-Directed DMD Drug
Nippon Shinyaku said on April 14 that the US FDA has agreed with its global PII clinical trial plan for NS-089/NCNP-02, an antisense oligonucleotide therapy for the treatment of Duchenne muscular dystrophy (DMD). The envisaged trial is slated to enroll…
To read the full story
Related Article
- Nippon Shinyaku’s DMD Drug Nabs Breakthrough Therapy Designation
July 31, 2023
- Nippon Shinyaku’s DMD Drug Gets Rare Pediatric Disease Tag in US
July 5, 2023
- Exon 44-Targeted DMD Drug Hits Goals in PI/II: NCNP/Nippon Shinyaku
March 18, 2022
- National Neurology Center Starts Investigator-Led Trial for DMD Drug Targeting Exon 44
November 8, 2019
BUSINESS
- J&J's Drug-Device Combo Offers Weeks-Long Local Therapy for Bladder Cancer: Exec
May 8, 2026
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…